SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 32.21 |
| Enterprise Value ($M) | 30.41 |
| Book Value ($M) | 0.75 |
| Book Value / Share | 0.02 |
| Price / Book | 43.16 |
| NCAV ($M) | -0.75 |
| NCAV / Share | -0.02 |
| Price / NCAV | -42.73 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -11.75 |
| Return on Assets (ROA) | -0.32 |
| Return on Equity (ROE) | -0.88 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.75 |
| Current Ratio | 0.75 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 2.24 |
| Assets | 3.74 |
| Liabilities | 2.99 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -7.31 |
| Net Income | -7.31 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -16.07 |
| Cash from Investing | 4.96 |
| Cash from Financing | 12.79 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D | Eureka Therapeutics, Inc. | 71.80 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 925 | 13,696 | 6.75 | |
| 3,614 | 18,032 | 20.04 | |
| 3,832 | 28,138 | 13.62 | |
| 850 | 3,959 | 21.47 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| EPIX – ESSA Pharma Inc. | EQ – Equillium, Inc. |
| ERNA – Eterna Therapeutics Inc. | EVOK – Evoke Pharma, Inc. |
| EYEN – Eyenovia, Inc. |
Financial data and stock pages provided by
Fintel.io